Rhett P Ketterling

List of Publications by Year in Descending Order

462 papers	14,515 citations	57 h-index	110 g-index
465 ext. papers	16,985 ext. citations	4.5 avg, IF	6 L-index

#	Paper	IF	Citations
462	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
461	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. *Blood Cancer Journal*, **2022**, 12, 26	7	1
460	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. *Haematologica*, **2022**,	6.6	1
459	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. *Leukemia Research*, **2022**, 106818	2.7	0
458	Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. *Blood Cancer Journal*, **2022**, 12, 44	7	1
457	Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature.. *Annals of Diagnostic Pathology*, **2022**, 58, 151942	2.2	0
456	Apparent coexistence of and fusions due to a nonproductive rearrangement in B-ALL.. *Leukemia and Lymphoma*, **2022**, 1-4	1.9	0
455	RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large cell lymphoma.. *Histopathology*, **2022**,	7.3	0
454	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. *American Journal of Hematology*, **2021**,	7.1	2
453	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. *Cancer Genetics*, **2021**, 260-261, 1-5	2.3	
452	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. *Blood Cancer Journal*, **2021**, 11, 184	7	0
451	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. *Blood*, **2021**, 138, 1267-1267	2.2	
450	Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. *Blood*, **2021**, 138, 3629-3629	2.2	
449	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. *Blood*, **2021**, 138, 3771-3771	2.2	0
448	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. *Blood*, **2021**, 138, 3368-3368	2.2	0
447	Cryptic t(6;11) KMT2A rearrangement in a pediatric acute myeloid leukemia patient detected by next-generation sequencing and dual-fusion FISH analysis. *Pediatric Blood and Cancer*, **2021**, e29428	3	
446	False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. *Blood*, **2021**, 138, 4101-4101	2.2	

445	Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 176-190	5	2
444	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. *American Journal of Surgical Pathology*, **2021**, 45, 550-557	6.7	3
443	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA venetoclax chemotherapy. *American Journal of Hematology*, **2021**, 96, E108-E111	7.1	3
442	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. *Blood Cancer Journal*, **2021**, 11, 46	7	1
441	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. *Blood Cancer Journal*, **2021**, 11, 54	7	1
440	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. *Leukemia*, **2021**, 35, 3329-3333	10.7	1
439	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. *Blood*, **2021**, 138, 948-958	2.2	7
438	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. *Blood Advances*, **2021**, 5, 2272-2278	7.8	3
437	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. *Genes Chromosomes and Cancer*, **2021**, 60, 678-686	5	1
436	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. *Human Pathology*, **2021**, 112, 20-34	3.7	2
435	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. *Leukemia*, **2021**, 35, 644-649	10.7	6
434	Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia. *Genes Chromosomes and Cancer*, **2021**, 60, 108-111	5	1
433	Lymphoma-like double-hit genetic abnormalities (and) in a case of non-secretory multiple myeloma. *Leukemia and Lymphoma*, **2021**, 62, 243-246	1.9	
432	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162	7.1	2
431	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. *Blood Cancer Journal*, **2021**, 11, 18	7	3
430	The Prognostic Role of Structural Variants Identified by NGS and FISH in Multiple Myeloma. *Clinical Cancer Research*, **2021**,	12.9	5
429	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. *British Journal of Haematology*, **2021**, 195, 413-416	4.5	1
428	Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. *Annals of Diagnostic Pathology*, **2021**, 53, 151761	2.2	0

427	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, 1450-1460	7.1	1
426	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. *Blood Cancer Journal*, **2021**, 11, 156	7	3
425	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, e710-e713	2	
424	A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review. *Cancer Genetics*, **2021**, 258-259, 69-73	2.3	0
423	Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. *Annals of Diagnostic Pathology*, **2020**, 46, 151533	2.2	3
422	Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation. *Journal of Heart and Lung Transplantation*, **2020**, 39, 1156-1158	5.8	0
421	The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. *Blood Cancer Journal*, **2020**, 10, 7	7	5
420	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. *Blood Cancer Journal*, **2020**, 10, 5	7	10
419	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. *American Journal of Clinical Pathology*, **2020**, 153, 656-663	1.9	6
418	Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. *British Journal of Haematology*, **2020**, 189, 291-302	4.5	58
417	Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. *American Journal of Hematology*, **2020**, 95, E86-E89	7.1	2
416	Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. *Cancer Genetics*, **2020**, 243, 48-51	2.3	2
415	Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen. *American Journal of Clinical Pathology*, **2020**, 153, 333-341	1.9	3
414	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. *Blood*, **2020**, 136, 9-10	2.2	
413	Heterogeneity of MYC Abnormalities in Multiple Myeloma. *Blood*, **2020**, 136, 2-3	2.2	
412	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 21-22	2.2	
411	Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma. *Blood*, **2020**, 136, 22-23	2.2	
410	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Advances*, **2020**, 4, 2236-2244	7.8	7

409	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Advances*, **2020**, 4, 5716-5721	7.8	5
408	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, E68-E72	7.1	2
407	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. *Cancer Genetics*, **2020**, 241, 67-71	2.3	1
406	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. *Cancer Genetics*, **2020**, 240, 40-44	2.3	3
405	Characterization of a cryptic fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative FISH studies. *Leukemia and Lymphoma*, **2020**, 61, 975-978	1.9	4
404	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588	12.9	9
403	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. *Annals of Diagnostic Pathology*, **2020**, 48, 151588	2.2	0
402	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Advances*, **2020**, 4, 3509-3519	7.8	27
401	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82	7	17
400	Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. *Histopathology*, **2020**, 76, 481-485	7.3	3
399	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. *Leukemia*, **2020**, 34, 656-661	10.7	17
398	Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. *Genes Chromosomes and Cancer*, **2020**, 59, 422-427	5	4
397	Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma. *BMC Clinical Pathology*, **2019**, 12, 2632010X19878410	1.3	5
396	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. *Blood Cancer Journal*, **2019**, 9, 12	7	28
395	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. *American Journal of Hematology*, **2019**, 94, E117-E120	7.1	6
394	Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. *Journal of Hematopathology*, **2019**, 12, 85-90	0.4	
393	Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. *Journal of Hematopathology*, **2019**, 12, 99-104	0.4	0
392	Elucidating a false-negative break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with and rearrangements. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	8

391	Recurrent mutations in ALK-negative anaplastic large cell lymphoma. *Blood*, **2019**, 133, 2776-2789	2.2	23
390	Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. *Leukemia*, **2019**, 33, 2522-2553	10.7	1
389	ADDENDUM: Section E9 of the American College of Medical Genetics Technical Standards and Guidelines: Fluorescence in situ hybridization. *Genetics in Medicine*, **2019**, 21, 2405	8.1	1
388	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
387	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. *Blood Cancer Journal*, **2019**, 9, 20	7	6
386	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Mayo Clinic Proceedings*, **2019**, 94, 599-610	6.4	50
385	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *American Journal of Hematology*, **2019**, 94, 767-779	7.1	27
384	A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia. *Genes Chromosomes and Cancer*, **2019**, 58, 665-668	5	1
383	Substratification of patients with newly diagnosed standard-risk multiple myeloma. *British Journal of Haematology*, **2019**, 185, 254-260	4.5	8
382	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. *Blood Cancer Journal*, **2019**, 9, 11	7	8
381	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 598-602	2	2
380	Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. *Cancer Genetics*, **2019**, 237, 51-54	2.3	3
379	Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. *Blood Cancer Journal*, **2019**, 9, 81	7	9
378	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 4396-4396	2.2	
377	Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections. *Blood*, **2019**, 134, 4282-4282	2.2	
376	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. *Blood*, **2019**, 134, 1800-1800	2.2	1
375	Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing. *Blood*, **2019**, 134, 5212-5212	2.2	
374	Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory. *Genes Chromosomes and Cancer*, **2019**, 58, 567-577	5	11

373	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20
372	Characterization of a cryptic rearrangement in a case of mantle cell lymphoma with negative FISH studies. *Blood Advances*, **2019**, 3, 1298-1302	7.8	11
371	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. *Leukemia Research*, **2019**, 87, 106264	2.7	
370	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. *Blood Cancer Journal*, **2019**, 9, 103	7	18
369	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5
368	Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. *Haematologica*, **2019**, 104, e147-e150	6.6	4
367	Calculator-free point-of-care prognostication in myelodysplastic syndromes. *American Journal of Hematology*, **2019**, 94, E99-E101	7.1	
366	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the V617F mutation. *Haematologica*, **2019**, 104, e236-e239	6.6	13
365	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. *American Journal of Hematology*, **2019**, 94, 111-117	7.1	19
364	Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. *Leukemia*, **2019**, 33, 780-785	10.7	2
363	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. *American Journal of Hematology*, **2019**, 94, 299-305	7.1	5
362	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. *American Journal of Hematology*, **2019**, 94, 286-290	7.1	3
361	Constitutional chromosome rearrangements that mimic the 2017 world health organization "acute myeloid leukemia with recurrent genetic abnormalities": A study of three cases and review of the literature. *Cancer Genetics*, **2019**, 230, 37-46	2.3	4
360	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. *American Journal of Hematology*, **2019**, 94, 5-9	7.1	3
359	Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. *Human Pathology*, **2019**, 89, 109-114	3.7	6
358	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 102, 87-96	3.8	23
357	U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia*, **2018**, 32, 2274-2278	10.7	47
356	The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E164-E167	7.1	1

355	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. *Leukemia*, **2018**, 32, 1631-1642	10.7	117
354	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. *Annals of Hematology*, **2018**, 97, 1453-1462	3	18
353	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
352	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. *Leukemia*, **2018**, 32, 1254-1258	10.7	26
351	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. *Leukemia*, **2018**, 32, 1200-1210	10.7	68
350	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer Journal*, **2018**, 8, 18	7	13
349	FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. *Leukemia and Lymphoma*, **2018**, 59, 1520-1522	1.9	5
348	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. *American Journal of Hematology*, **2018**, 93, 649-654	7.1	26
347	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. *Leukemia*, **2018**, 32, 1189-1199	10.7	65
346	Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. *American Journal of Hematology*, **2018**, 93, 691-697	7.1	34
345	Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. *Blood Cancer Journal*, **2018**, 8, 8	7	0
344	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. *Blood Cancer Journal*, **2018**, 8, 12	7	30
343	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. *British Journal of Haematology*, **2018**, 183, 835-838	4.5	23
342	Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement. *Cancer Genetics*, **2018**, 220, 13-18	2.3	3
341	Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. *British Journal of Haematology*, **2018**, 182, 437-440	4.5	14
340	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. *Leukemia*, **2018**, 32, 1850-1856	10.7	19
339	Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. *Blood* , **2018**, 131, 2262-2266	2.2	45
338	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. *Leukemia and Lymphoma*, **2018**, 59, 2998-3001	1.9	5

337	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. *Blood Cancer Journal*, **2018**, 8, 32	7	9
336	Momelotinib therapy for myelofibrosis: a 7-year follow-up. *Blood Cancer Journal*, **2018**, 8, 29	7	27
335	Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. *British Journal of Haematology*, **2018**, 182, 594-597	4.5	18
334	Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. *American Journal of Hematology*, **2018**, 93, 65-73	7.1	37
333	Revisiting the need for bone marrow examination in chronic myeloid leukemia. *American Journal of Hematology*, **2018**, 93, 5-7	7.1	1
332	Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 57	7	17
331	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. *American Journal of Clinical Pathology*, **2018**, 150, 421-431	1.9	6
330	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review. *American Journal of Clinical Pathology*, **2018**, 150, 375-384	1.9	9
329	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. *American Journal of Hematology*, **2018**, 93, E235-E238	7.1	7
328	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. *Leukemia Research*, **2018**, 71, 60-62	2.7	11
327	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia*, **2018**, 32, 2512-2518	10.7	19
326	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. *Blood Advances*, **2018**, 2, 1980-1984	7.8	8
325	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. *American Journal of Hematology*, **2018**, 93, 1461-1466	7.1	17
324	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. *American Journal of Hematology*, **2018**, 93, 1347-1357	7.1	7
323	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clinic Proceedings*, **2018**, 93, 1363-1374	6.4	14
322	Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements. *Haematologica*, **2018**, 103, 1899-1907	6.6	31
321	Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. *American Journal of Hematology*, **2018**, 93, 1074-1081	7.1	45
320	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. *Blood*, **2018**, 132, 544-547	17.2	60

319	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). *Blood*, **2018**, 132, 578-578	2.2	5
318	20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. *Blood*, **2018**, 132, 4301-4301	2.2	0
317	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Blood*, **2018**, 132, 3035-3035	2.2	1
316	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. *Blood*, **2018**, 132, 3040-3040	2.2	1
315	High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?. *Blood*, **2018**, 132, 1693-1693	2.2	1
314	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2	
313	Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. *Blood*, **2018**, 132, 4300-4300	2.2	
312	Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort. *Blood*, **2018**, 132, 3987-3987	2.2	
311	Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. *Blood*, **2018**, 132, 3034-3034	2.2	
310	The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. *Blood*, **2018**, 132, 1761-1761	2.2	
309	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. *Blood*, **2018**, 132, 4287-4287	2.2	
308	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. *Blood*, **2018**, 132, 582-582	2.2	
307	Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. *Blood*, **2018**, 132, 1767-1767	2.2	
306	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. *Blood*, **2018**, 132, 3050-3050	2.2	
305	Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. *Blood*, **2018**, 132, 3033-3033	2.2	
304	Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. *Blood*, **2018**, 132, 4291-4291	2.2	
303	Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm. *Blood*, **2018**, 132, 4382-4382	2.2	
302	MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. *Blood*, **2018**, 132, 3036-3036	2.2	

301	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. *Blood*, **2018**, 132, 3100-3100	2.2	
300	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. *Blood*, **2018**, 132, 2678-2678	2.2	
299	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. *Blood*, **2018**, 132, 2689-2689	2.2	
298	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. *Blood*, **2018**, 132, 3044-3044	2.2	
297	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. *Blood*, **2018**, 132, 1771-1771	2.2	
296	Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. *American Journal of Hematology*, **2018**, 93, 348-355	7.1	54
295	Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. *British Journal of Haematology*, **2018**, 183, 678-681	4.5	10
294	Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms. *Leukemia and Lymphoma*, **2018**, 59, 1913-1919	1.9	2
293	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. *Journal of Clinical Oncology*, **2018**, 36, 310-318	2.2	224
292	MPL-mutated essential thrombocythemia: a morphologic reappraisal. *Blood Cancer Journal*, **2018**, 8, 121	7	13
291	Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. *Blood Cancer Journal*, **2018**, 8, 118	7	3
290	Genetic predictors of response to specific drugs in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 120	7	0
289	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with rearrangements. *Blood*, **2018**, 132, 1386-1398	2.2	44
288	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. *American Journal of Hematology*, **2018**, 93, E401-E404	7.1	2
287	KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. *Genes Chromosomes and Cancer*, **2018**, 57, 541-546	5	16
286	Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia. *Case Reports in Hematology*, **2018**, 2018, 7456378	0.7	1
285	Mutations and karyotype predict treatment response in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, 1420-1426	7.1	18
284	Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. *American Journal of Hematology*, **2018**, 93, E383-E386	7.1	2

283	Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. *American Journal of Hematology*, **2018**, 93, 1474-1484	7.1	31
282	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. *Blood Advances*, **2018**, 2, 370-380	7.8	55
281	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Advances*, **2018**, 2, 2964-2972	7.8	40
280	Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. *Human Pathology*, **2017**, 64, 19-27	3.7	31
279	FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. *Pediatric Blood and Cancer*, **2017**, 64, e26450	3	13
278	CD36-positive B-lymphoblasts Predict Poor Outcome in Children With B-lymphoblastic Leukemia. *Pediatric and Developmental Pathology*, **2017**, 20, 224-231	2.2	4
277	Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. *Human Pathology*, **2017**, 64, 207-212	3.7	5
276	The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. *British Journal of Haematology*, **2017**, 178, 57-60	4.5	2
275	and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. *Blood*, **2017**, 130, 554-557	2.2	68
274	Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. *Leukemia Research*, **2017**, 59, 55-64	2.7	15
273	Monocytosis in polycythemia vera: Clinical and molecular correlates. *American Journal of Hematology*, **2017**, 92, 640-645	7.1	31
272	Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 542-548	7.1	41
271	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82
270	Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. *American Journal of Hematology*, **2017**, 92, 1311-1317	7.1	50
269	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. *American Journal of Hematology*, **2017**, 92, E614-E618	7.1	20
268	Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. *American Journal of Hematology*, **2017**, 92, 1187-1192	7.1	17
267	Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. *American Journal of Hematology*, **2017**, 92, 1193-1197	7.1	18
266	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. *American Journal of Hematology*, **2017**, 92, 56-61	7.1	48

265	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1488-1493	1.9	35
264	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. *Blood Cancer Journal*, **2017**, 7, 657	7	5
263	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). *Blood Cancer Journal*, **2017**, 7, 658	7	13
262	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. *Blood*, **2017**, 130, 822-822	2.2	6
261	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Advances*, **2016**, 1, 21-30	7.8	163
260	Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American	2.2	68
259	Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *British Journal of Haematology*, **2016**, 172, 384-91	4.5	49
258	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2016**, 6, e385	7	83
257	LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. *American Journal of Clinical Pathology*, **2016**, 145, 180-90	1.9	13
256	Is It Time for a New Gold Standard? FISH vs Cytogenetics in AML Diagnosis. *American Journal of Clinical Pathology*, **2016**, 145, 430-2	1.9	5
255	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. *Blood*, **2016**, 128, 1123-1123	2.2	4
254	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). *Blood*, **2016**, 128, 155-155	2.2	1
253	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". *Blood*, **2016**, 128, 1750-1750	2.2	2
252	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. *Blood*, **2016**, 128, 2798-2798	2.2	3
251	Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 3113-3113	2.2	2
250	Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. *Blood*, **2016**, 128, 3115-3115	2.2	1
249	Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. *Blood*, **2016**, 128, 4247-4247	2.2	2
248	U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. *Blood*, **2016**, 128, 4248-4248	2.2	1

247	Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. *Blood*, **2016**, 128, 4249-4249	2.2	2
246	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 4343-4343	2.2	1
245	Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. *Blood*, **2016**, 128, 948-948	2.2	1
244	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. *Blood*, **2016**, 128, 1987-1987	2.2	0
243	Unique Clinical Epidemiologic Risk Factors Are Associated with Distinct Methylation Subgroups in Newly-Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1719-1719	2.2	0
242	Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. *Blood*, **2016**, 128, 3129-3129	2.2	
241	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. *Blood*, **2016**, 128, 1996-1996	2.2	
240	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615	2.2	
239	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. *Blood*, **2016**, 128, 4259-4259	2.2	
238	Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. *Blood*, **2016**, 128, 4086-4086	2.2	
237	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 110-110	2.2	
236	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269	2.2	
235	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. *Blood*, **2016**, 128, 1986-1986	2.2	
234	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. *Blood*, **2016**, 128, 5534-5534	2.2	0
233	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. *Blood*, **2016**, 128, 3255-3255	2.2	
232	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1988-1988	2.2	
231	Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. *Blood*, **2016**, 128, 3452-3452	2.2	
230	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. *Blood* , **2016**, 128, 5542-5542	2.2	

229	Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. *Blood*, **2016**, 128, 3111-3111	2.2	
228	Novel Mutations in NOTCH and Altered Wnt/Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. *Blood*, **2016**, 128, 4103-4103	2.2	1
227	Targeted deep sequencing in primary myelofibrosis. *Blood Advances*, **2016**, 1, 105-111	7.8	120
226	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. *American Journal of Surgical Pathology*, **2016**, 40, 36-43	6.7	70
225	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. *American Journal of Hematology*, **2016**, 91, 492-8	7.1	55
224	A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). *American Journal of Hematology*, **2016**, 91, 308-12	7.1	9
223	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. *American Journal of Clinical Pathology*, **2016**, 146, 86-94	1.9	14
222	Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. *American Journal of Hematology*, **2016**, 91, 888-93	7.1	47
221	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. *Blood*, **2016**, 127, 1551-8	2.2	81
220	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. *Leukemia Research*, **2016**, 50, 112-115	2.7	4
219	ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. *British Journal of Haematology*, **2016**, 175, 534-536	4.5	19
218	Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. *American Journal of Hematology*, **2016**, 91, 503-6	7.1	37
217	Concurrent activating KIT mutations in systemic mastocytosis. *British Journal of Haematology*, **2016**, 173, 153-6	4.5	11
216	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. *Blood Cancer Journal*, **2015**, 5, e270	7	21
215	Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. *American Journal of Clinical Pathology*, **2015**, 143, 873-8	1.9	16
214	Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. *Modern Pathology*, **2015**, 28, 359-66	9.8	10
213	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. *Mayo Clinic Proceedings*, **2015**, 90, 1623-38	6.4	10
212	Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. *American Journal of Clinical Pathology*, **2015**, 144, 493-502	1.9	10

211	Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. *Cancer Epidemiology*, **2015**, 39, 1084-92	2.8	23
210	Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. *European Journal of Haematology*, **2015**, 94, 31-6	3.8	35
209	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-ΚΒ positive feedback loop in peripheral T-cell lymphoma. *Blood*, **2015**, 125, 3118-27	2.2	47
208	Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. *Applied Immunohistochemistry and Molecular Morphology*, **2015**, 23, 580-9	1.9	8
207	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. *American Journal of Hematology*, **2015**, 90, 411-6	7.1	45
206	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 699-704	2	10
205	A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. *British Journal of Haematology*, **2015**, 169, 71-6	4.5	26
204	Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2015**, 5, e275	7	35
203	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. *Blood*, **2015**, 126, 1308-1308	2.2	5
202	Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. *Blood*, **2015**, 126, 1599-1599	2.2	1
201	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. *Blood*, **2015**, 126, 2801-2801	2.2	1
200	A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. *Blood*, **2015**, 126, 350-350	2.2	1
199	Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. *Blood* , **2015**, 126, 354-354	2.2	9
198	ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. *Blood*, **2015**, 126, 828-828	2.2	2
197	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). *Blood*, **2015**, 126, 4067-4067	2.2	
196	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. *Blood*, **2015**, 126, 4062-4062	2.2	
195	Molecular Correlates of Anemia in Primary Myelofibrosis. *Blood*, **2015**, 126, 4068-4068	2.2	
194	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. *Blood*, **2015**, 126, 2875-2875	2.2	

193	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2015**, 126, 2864-2864	2.2	
192	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. *Blood*, **2015**, 126, 1401-1401	2.2	
191	Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. *Blood*, **2015**, 126, 2805-2805	2.2	
190	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176	2.2	
189	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. *Blood*, **2015**, 126, 2882-2882	2.2	
188	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *American Journal of Hematology*, **2014**, 89, E121-4	7.1	145
187	A leukemic presentation of a "triple-hit" lymphoma. *Blood*, **2014**, 123, 1126	2.2	5
186	Development of an NPM1/MLF1 D-FISH probe set for the detection of t(3;5)(q25;q35) identified in patients with acute myeloid leukemia. *Journal of Molecular Diagnostics*, **2014**, 16, 527-532	5.1	5
185	Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. *Journal of Clinical Oncology*, **2014**, 32, 1242-8	2.2	187
184	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*, **2014**, 124, 2507-13; quiz 2615	2.2	424
183	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood*, **2014**, 124, 1473-80	2.2	294
182	The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. *Blood*, **2014**, 124, 2465-6	2.2	105
181	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. *Leukemia*, **2014**, 28, 2206-12	10.7	186
180	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. *American Journal of Hematology*, **2014**, 89, 1111-5	7.1	104
179	Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders. *American Journal of Surgical Pathology*, **2014**, 38, 1203-11	6.7	34
178	Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization. *Journal of the American Academy of Dermatology*, **2014**, 70, 1021-7	4.5	49
177	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. *Leukemia*, **2013**, 27, 1504-10	10.7	151
176	Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. *Leukemia and Lymphoma*, **2013**, 54, 1534-7	1.9	2

175	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. *American Journal of Hematology*, **2013**, 88, 690-3	7.1	29
174	Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. *Blood*, **2013**, 122, e33-43	2.2	36
173	Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. *American Journal of Surgical Pathology*, **2013**, 37, 1173-81	6.7	125
172	Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. *American Journal of Hematology*, **2013**, 88, 201-6	7.1	112
171	Atypical generalized eruptive histiocytosis clonally related to chronic myelomonocytic leukemia with loss of Y chromosome. *Journal of Cutaneous Pathology*, **2013**, 40, 725-9	1.7	14
170	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. *European Journal of Haematology*, **2013**, 91, 193-5	3.8	1
169	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. *Leukemia*, **2013**, 27, 2100-2	10.7	75
168	Cutaneous extramedullary plasmacytoma: clinical, prognostic, and interphase cytogenetic analysis. *American Journal of Dermatopathology*, **2013**, 35, 357-63	0.9	8
167	A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. *American Journal of Surgical Pathology*, **2013**, 37, 147-51	6.7	12
166	Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. *American Journal of Surgical Pathology*, **2013**, 37, 978-86	6.7	60
165	t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. *PLoS ONE*, **2013**, 8, e53767	3.7	29
164	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. *Blood*, **2013**, 122, 104-104	2.2	3
163	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. *Blood*, **2013**, 122, 1510-1510	2.2	2
162	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. *Blood*, **2013**, 122, 2821-2821	2.2	1
161	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. *Blood*, **2013**, 122, 3210-3210	2.2	2
160	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. *Blood*, **2013**, 122, 1587-1587	2.2	
159	U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. *Blood*, **2013**, 122, 4060-4060	2.2	
158	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. *Blood*, **2013**, 122, 4955-4955	2.2	

157	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1334-1334	2.2	
156	Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. *Blood*, **2013**, 122, 2777-2777	2.2	
155	Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. *Blood*, **2013**, 122, 3016-3016	2.2	
154	Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. *Leukemia Research*, **2012**, 36, 59-66	2.7	10
153	TP53 mutations and polymorphisms in primary myelofibrosis. *American Journal of Hematology*, **2012**, 87, 204-6	7.1	10
152	Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. *Blood*, **2012**, 120, 1290-8	2.2	123
151	CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. *Blood*, **2012**, 120, 2297-306	2.2	78
150	Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. *Blood*, **2012**, 119, 5674-7	2.2	59
149	SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. *Blood*, **2012**, 120, 4168-71	2.2	128
148	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood*, **2012**, 119, 569-72	2.2	164
147	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood*, **2012**, 119, 2100-5	2.2	181
146	One thousand patients with primary myelofibrosis: the mayo clinic experience. *Mayo Clinic Proceedings*, **2012**, 87, 25-33	6.4	137
145	When are apparently non-clonal abnormalities in bone marrow chromosome studies actually clonal?. *Cancer Genetics*, **2012**, 205, 405-9	2.3	2
144	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *New England Journal of Medicine*, **2012**, 366, 1079-89	59.2	1378
143	Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. *Journal of Clinical Oncology*, **2012**, 30, 1087-94	2.2	22
142	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. *Leukemia*, **2012**, 26, 101-5	10.7	112
141	ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 623-6	5	39
140	Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. *American Journal of Clinical Pathology*, **2012**, 137, 270-6	1.9	24

139	Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. *Cancer Discovery*, **2012**, 2, 1004-23	24.4	70
138	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. *Blood*, **2012**, 120, 2280-9	2.2	164
137	Treatment-influenced associations of PML-RAR mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. *Blood*, **2012**, 120, 2098-108	2.2	46
136	Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. *Blood*, **2012**, 120, 2851-2851	2.2	4
135	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. *Blood*, **2012**, 120, 676-676	2.2	1
134	Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. *International Journal of Clinical and Experimental Pathology*, **2012**, 5, 72-6	1.4	9
133	Identification of t(1;19)(q12;p13) and ploidy changes in an ependymosarcoma: a cytogenetic evaluation **2012**, 31, 142-5		3
132	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. *Blood*, **2012**, 120, 1711-1711	2.2	
131	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with 1% Ring Sideroblasts.. *Blood*, **2012**, 120, 2803-2803	2.2	
130	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. *Blood*, **2012**, 120, 1875-1875	2.2	
129	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. *Blood*, **2012**, 120, 3790-3790	2.2	
128	Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. *Blood*, **2012**, 120, 430-430	2.2	
127	T(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 Via STAT5. *Blood*, **2012**, 120, 1567-1567	2.2	
126	The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. *Blood*, **2012**, 120, 1742-1742	2.2	
125	Microgranular variant of acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR. *Cancer Genetics*, **2011**, 204, 522-3	2.3	10
124	Clinicopathologic and genetic characterization of follicular lymphomas presenting in the ovary reveals 2 distinct subgroups. *American Journal of Surgical Pathology*, **2011**, 35, 1691-9	6.7	11
123	A case of hairy cell leukemia with CCND1-IGH@ translocation: indolent non-nodal mantle cell lymphoma revisited. *American Journal of Surgical Pathology*, **2011**, 35, 1080-4	6.7	7
122	Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. *Blood*, **2011**, 117, 5306-13	2.2	53

121	Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. *Blood*, **2011**, 117, e190-7	2.2	36
120	Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. *Pediatric Blood and Cancer*, **2011**, 56, 307-10	3	45
119	Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion. *Pediatric Blood and Cancer*, **2011**, 56, 467-9	3	11
118	Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. *American Journal of Hematology*, **2011**, 86, 393-8	7.1	18
117	The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. *International Journal of Cancer*, **2011**, 128, 2759-64	7.5	16
116	C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2011**, 29, 651-9	2.2	49
115	Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. *American Journal of Clinical Pathology* , **2011**, 135, 686-96	1.9	30
114	Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. *Genetics in Medicine*, **2011**, 13, 667-75	8.1	52
113	Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. *Modern Pathology*, **2011**, 24, 1421-32	9.8	135
112	Reflex fluorescent in situ hybridization testing for unsuccessful product of conception cultures: a retrospective analysis of 5555 samples attempted by conventional cytogenetics and fluorescent in situ hybridization. *Genetics in Medicine*, **2011**, 13, 545-52	8.1	52
111	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. *Blood*, **2011**, 118, 460-460	2.2	0
110	Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 915-9	5	9
109	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. *Blood*, **2011**, 118, 3803-3803	2.2	
108	The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999. *Blood*, **2011**, 118, 2568-2568	2.2	
107	Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. *Blood*, **2011**, 118, 3619-3619	2.2	
106	Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. *Blood*, **2011**, 118, 1756-1756	2.2	
105	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. *Blood*, **2011**, 118, 971-971	2.2	
104	TP53 mutations and Polymorphisms in Primary Myelofibrosis,. *Blood*, **2011**, 118, 3840-3840	2.2	

103	WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. *Leukemia*, **2010**, 24, 1283-9	10.7	72
102	Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). *Leukemia*, **2010**, 24, 1370-2	10.7	42
101	Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception. *American Journal of Clinical Pathology*, **2010**, 133, 196-204	1.9	24
100	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2010**, 28, 4307-15	2.2	175
99	Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. *Mayo Clinic Proceedings*, **2010**, 85, 532-7	6.4	52
98	Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. *Human Pathology*, **2010**, 41, 103-6	3.7	36
97	Isochromosome 12p and polysomy 12 in primary central nervous system germ cell tumors: frequency and association with clinicopathologic features. *Human Pathology*, **2010**, 41, 232-8	3.7	21
96	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood*, **2010**, 116, 4077-85	2.2	157
95	Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners. *Journal of Molecular Diagnostics*, **2010**, 12, 441-52	5.1	9
94	Nearly identical near-haploid karyotype in a peritoneal mesothelioma and a retroperitoneal malignant peripheral nerve sheath tumor. *Cancer Genetics and Cytogenetics*, **2010**, 202, 123-8		14
93	Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. *European Journal of Haematology*, **2010**, 84, 191-200	3.8	21
92	Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. *European Journal of Haematology*, **2010**, 84, 518-24	3.8	21
91	Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. *European Journal of Haematology*, **2010**, 85, 86-7	3.8	10
90	Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. *American Journal of Hematology*, **2010**, 85, 238-42	7.1	31
89	Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia. *American Journal of Hematology*, **2010**, 85, 569-74	7.1	15
88	Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases. *Leukemia Research*, **2010**, 34, e71-3	2.7	25
87	Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. *American Journal of Clinical Pathology*, **2009**, 131, 663-70	1.9	27
86	Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. *Cancer Research*, **2009**, 69, 7518-23	10.1	29

85	Anthracycline dose intensification in acute myeloid leukemia. *New England Journal of Medicine*, **2009**, 361, 1249-59	59.2	658
84	Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. *European Journal of Haematology*, **2009**, 82, 255-9	3.8	47
83	Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. *European Journal of Haematology*, **2009**, 83, 17-21	3.8	53
82	Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2009**, 454, 431-9	5.1	28
81	Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. *Leukemia Research*, **2009**, 33, 843-6	2.7	14
80	CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. *Human Pathology*, **2009**, 40, 1296-303	3.7	28
79	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*, **2009**, 114, 5136-45	2.2	277
78	Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. *Blood*, **2009**, 113, 1200-1	2.2	14
77	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. *Haematologica*, **2009**, 94, 380-6	6.6	80
76	Rosette-forming glioneuronal tumor: report of a chiasmal-optic nerve example in neurofibromatosis type 1: special pathology report. *Neurosurgery*, **2009**, 64, E771-2; discussion E772	3.2	56
75	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. *Blood*, **2009**, 114, 2785-2785	2.2	
74	Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.. *Blood*, **2009**, 114, 3937-3937	2.2	3
73	Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.. *Blood*, **2009**, 114, 1802-1802	2.2	
72	Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.. *Blood*, **2009**, 114, 3405-3405	2.2	
71	Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. *European Journal of Haematology*, **2008**, 80, 197-200	3.8	56
70	Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. *European Journal of Haematology*, **2008**, 80, 318-21	3.8	7
69	Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. *American Journal of Clinical Pathology*, **2008**, 129, 478-85	1.9	24
68	Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. *Blood*, **2008**, 112, 1931-41	2.2	54

67	Pituitary blastoma. *Acta Neuropathologica*, **2008**, 116, 657-66	14.3	51
66	A novel report of cig-FISH and cytogenetics in POEMS syndrome. *American Journal of Hematology*, **2008**, 83, 840-1	7.1	12
65	Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. *Leukemia Research*, **2008**, 32, 407-11	2.7	14
64	Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. *Leukemia Research*, **2008**, 32, 1597-600	2.7	5
63	Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. *Leukemia Research*, **2008**, 32, 1927-30	2.7	15
62	Anaplastic Angiocentric Glioma: A Report of Two Cases. *FASEB Journal*, **2008**, 22, 706.4	0.9	1
61	Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution. *Blood*, **2008**, 112, 2523-2523	2.2	
60	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. *Blood*, **2008**, 112, 1707-1707	2.2	
59	Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS). *Blood*, **2008**, 112, 2679-2679	2.2	
58	Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. *Leukemia and Lymphoma*, **2007**, 48, 2137-40	1.9	2
57	Evaluation of a commercially available focused aCGH platform for the detection of constitutional chromosome anomalies. *American Journal of Medical Genetics, Part A*, **2007**, 143A, 2357-70	2.5	19
56	Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. *Cancer*, **2007**, 109, 2279-84	6.4	132
55	An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. *Leukemia Research*, **2007**, 31, 1145-8	2.7	23
54	Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. *Modern Pathology* , **2007**, 20, 592-603	9.8	83
53	Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia. *Cancer Genetics and Cytogenetics* , **2007**, 175, 8-18		13
52	Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. *Stem Cells*, **2007**, 25, 2358-62	5.8	55
51	Comprehensive validation of array comparative genomic hybridization platforms: how much is enough?. *Genetics in Medicine*, **2007**, 9, 632-41	8.1	10
50	Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system. *Journal of Molecular Diagnostics*, **2007**, 9, 144-50	5.1	14

49	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. *Blood*, **2007**, 110, 2477-2477	2.2	1
48	Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.. *Blood*, **2007**, 110, 3504-3504	2.2	
47	Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. *Genes Chromosomes and Cancer*, **2006**, 45, 1111-20	5	35
46	Preclinical validation of fluorescence in situ hybridization assays for clinical practice. *Genetics in Medicine*, **2006**, 8, 16-23	8.1	81
45	Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. *Leukemia and Lymphoma* , **2006**, 47, 2055-61	1.9	18
44	Splenic small B-cell lymphoma with IGH/BCL3 translocation. *Human Pathology*, **2006**, 37, 218-30	3.7	22
43	Lenalidomide therapy in myelofibrosis with myeloid metaplasia. *Blood*, **2006**, 108, 1158-64	2.2	211
42	Test Samples and Laboratory Protocols **2006**, 292-339		
41	Functioning paraganglioma and gastrointestinal stromal tumor of the jejunum in three women: syndrome or coincidence. *American Journal of Surgical Pathology*, **2006**, 30, 42-9	6.7	28
40	FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. *Leukemia Research*, **2006**, 30, 965-70	2.7	110
39	Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.. *Blood*, **2006**, 108, 4783-4783	2.2	
38	Idiopathic Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFRA Status, and Clinical Course.. *Blood*, **2006**, 108, 2701-2701	2.2	
37	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. *Blood*, **2006**, 108, 3587-3587	2.2	
36	Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. *Blood*, **2005**, 105, 973-7	2.2	305
35	Molecular diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. *Diagnostic Molecular Pathology*, **2005**, 14, 23-8		60
34	Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. *Blood*, **2005**, 106, 3553-8	2.2	100
33	Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. *British Journal of Haematology*, **2005**, 129, 45-52	4.5	16
32	Analysis of Intratumoral Heterogeneity and Amplification Status in Breast Carcinomas With Equivocal (2+) HER-2 Immunostaining. *American Journal of Clinical Pathology*, **2005**, 124, 273-281	1.9	73

31	Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. *American Journal of Clinical Pathology*, **2005**, 124, 273-81	1.9	19
30	Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.. *Blood*, **2005**, 106, 624-624	2.2	1
29	Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. *Blood*, **2005**, 106, 2590-2590	2.2	
28	FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood*, **2004**, 104, 3038-45	2.2	248
27	Familial 22q11.2 deletions in DiGeorge/velocardiofacial syndrome are predominantly smaller than the commonly observed 3Mb. *Genetics in Medicine*, **2004**, 6, 517-20	8.1	17
26	Bone Marrow Histologic and Cytogenetic Changes during Leukemic Transformation of Myelofibrosis with Myeloid Metaplasia.. *Blood*, **2004**, 104, 4750-4750	2.2	
25	Discovery of 6 Novel Translocations Involving the Imatinib Responsive Genes PDGFRB and PDGFRB from Screening 29,047 Abnormal Bone Marrow Specimens.. *Blood*, **2004**, 104, 2902-2902	2.2	2
24	CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood*, **2003**, 102, 3093-6	2.2	327
23	New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. *Cancer Genetics and Cytogenetics*, **2003**, 145, 144-51		52
22	Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. *British Journal of Haematology*, **2003**, 123, 366-7	4.5	2
21	Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. *American Journal of Human Genetics*, **2003**, 73, 1027-40	11	298
20	Utility of subtelomeric fluorescent DNA probes for detection of chromosome anomalies in 425 patients. *Genetics in Medicine*, **2003**, 5, 28-34	8.1	49
19	Histologic and Immunohistochemical Study of Bone Marrow Monocytic Nodules in 21 Cases With Myelodysplasia. *American Journal of Clinical Pathology*, **2003**, 120, 874-881	1.9	1
18	Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. *Leukemia Research*, **2002**, 26, 235-40	2.7	57
17	Inherited interstitial deletion of chromosomes 5p and 16q without apparent phenotypic effect: further confirmation. *Prenatal Diagnosis*, **2000**, 20, 144-8; discussion 149-51	3.2	27
16	Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations. *Human Mutation*, **1999**, 13, 221-31	4.7	45
15	Germline mutations in Peruvian patients with hemophilia B: pattern of mutation in AmerIndians is similar to the putative endogenous germline pattern. *Human Mutation*, **1998**, 11, 372-6	4.7	10
14	The factor IX gene as a model for analysis of human germline mutations: an update. *Human Molecular Genetics*, **1996**, 5 Spec No, 1505-14	5.6	43

13	Absence of somatic mosaicism in 17 families with hemophilia B: an analysis with a sensitivity 10- to 1000-fold greater than that of sequencing gels. *Human Genetics*, **1996**, 98, 539-45	6.3	10
12	Two novel factor IX promoter mutations: incremental progress towards 'saturation in vivo mutagenesis' of a human promoter region. *Human Molecular Genetics*, **1995**, 4, 769-70	5.6	11
11	Molecular Epidemiology of Factor IX Germline Mutations in Mexican Hispanics: Pattern of Mutation and Potential Founder Effects. *Thrombosis and Haemostasis*, **1995**, 74, 1416-1422	7	15
10	Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. *Human Molecular Genetics*, **1994**, 3, 1035-9	5.6	144
9	"Cryptic" dinucleotide polymorphism in the 3' region of the factor IX gene shows substantial variation among different populations. *Human Genetics*, **1994**, 93, 357-8	6.3	10
8	How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: lesions from the human factor IX gene. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1994**, 307, 517-31	3.3	15
7	A mutation in the 3' untranslated region of the factor IX gene in four families with hemophilia B. *Human Molecular Genetics*, **1993**, 2, 1309-10	5.6	18
6	Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-Caucasians. *Human Molecular Genetics*, **1993**, 2, 293-8	5.6	28
5	Deletions with inversions: report of a mutation and review of the literature. *Human Mutation*, **1993**, 2, 53-7	4.7	21
4	The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. *Human Genetics*, **1993**, 91, 496-503	6.3	37
3	PRE: a novel element with the hallmarks of a retrotransposon derived from an unknown structural RNA. *Nucleic Acids Research*, **1992**, 20, 5233	20.1	2
2	Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. *Genomics*, **1991**, 10, 1093-6	4.3	54
1	A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B. *British Journal of Haematology*, **1990**, 75, 212-6	4.5	33